Showing 3111-3120 of 5956 results for "".
- Web Vision Technologies Receives Grants to Develop Vision Testing Devices for NASAhttps://modernod.com/news/web-vision-technologies-receives-grants-to-develop-vision-testing-devices-for-nasa/2479953/Web Vision Technologies was recently awarded two grants from Translational Research Institute for Space Health (TRISH) at Baylor College of Medicine to develop vision-testing devices for the National Aeronautical Space Administration (NASA) to be used on the International Space Station (ISS). The
- Trabeculectomy Outcomes Different for Individuals of African vs European Descenthttps://modernod.com/news/trabeculectomy-outcomes-different-for-patients-of-african-vs-european-descent/2479955/Individuals of African descent (AD) and those of European descent (ED) tend to have different outcomes after trabeculectomy with mitomycin C, according to a report in JAMA Ophthalmology. “African descent was associate
- Glaukos Announces Pharmaceutical Development Agreement with D. Western Therapeutics Institutehttps://modernod.com/news/glaukos-announces-pharmaceutical-development-agreement-with-d-western-therapeutics-institute/2479956/Glaukos announced it has entered into a research and development collaboration agreement with D. Western Therapeutics Institute (DWTI), a Japanese biotechnology company focused on the discovery and development of innovative new drugs to serve patients worldwide. Under the agreement, Glauko
- Wills Eye Sponsors First Early Feasibility Study of a New Implantable Device for Blind Retinitis Pigmentosa Patientshttps://modernod.com/news/wills-eye-sponsors-first-us-early-feasibility-study-of-a-new-implantable-device-for-blind-retinitis-pigmentosa-patients/2479960/Wills Eye Hospital has been given FDA approval to begin an early feasibility study (EFS) to implant the RETINA IMPLANT Alpha AMS sub-retinal device in patients blind due to retinitis pigmentosa (RP). The Alpha AMS is manufactured by Retina Implant AG, Reutlingen,
- Aerie Pharmaceuticals and DSM Biomedical Expand Collaboration Agreement Focused on Novel Drug Delivery Technology in Ophthalmologyhttps://modernod.com/news/aerie-pharmaceuticals-and-dsm-biomedical-expand-collaboration-agreement-focused-on-novel-drug-delivery-technology-in-ophthalmology/2479966/Aerie Pharmaceuticals and DSM Biomedical reported that they have expanded their collaborative research, development, and license agreement. In July 2017, Aerie announced that it had entered into a research collaboration and license option agreement with DSM for purposes of evaluating the s
- RadianceTx Raises $1 Million First Tranche to Develop Novel Glaucoma Therapyhttps://modernod.com/news/radiancetx-raises-1-million-first-tranche-to-develop-novel-glaucoma-therapy/2479970/RadianceTx announced a $1 million first tranche closing of a targeted $7 million round of financing. The investment will be used to fund development of the company’s Beta Ophthalmic System for delivery of beta irradiation therapy to improve glaucoma surgery outcomes. Validated in three cli
- Glaucoma Research Foundation Grant Leads to Breakthrough in Neuron Regenerationhttps://modernod.com/news/glaucoma-research-foundation-grant-leads-to-breakthrough-in-neuron-regeneration/2479971/The Glaucoma Research Foundation announced a team of neuroscience researchers, led by Adriana Di Polo, PhD, at the University of Montreal, have made a major breakthrough in the treatment of glaucoma. The research, which was made possible by a Glaucoma Research Foundation Shaffer Grant, could also
- AAO Launches New Scientific Journal Dedicated to Glaucoma Researchhttps://modernod.com/news/aao-launches-new-scientific-journal-dedicated-to-glaucoma-research/2479972/The American Academy of Ophthalmology announced the launch of Ophthalmology Glaucoma, a scientific journal focused exclusively on glaucoma. As development of next-generation glaucoma devices and drugs surges, Ophthalmology Glaucoma offers researchers an expanded opportunity to pu
- Topical Presbyopia Treatment Advances in Clinical Developmenthttps://modernod.com/news/presbyopia-therapies-announces-primary-safety-and-efficacy-resutls-in-phase-2b-study-of-topical-presbyopia-treatment/2479978/Presbyopia Therapies announced that the primary efficacy and safety endpoints have been met in a phase 2b study of its PRX ophthalmic solution. PRX demonstrated a 3 line or greater improvement in monocular distance corrected near acuity in patients between the ages of 48 and 64, with this improve
- OCT Angiography Predicts Exudation in Macular Degenerationhttps://modernod.com/news/oct-angiography-predicts-exudation-in-macular-degeneration/2479981/Optical coherence tomography (OCT) angiography can help predict which eyes affected by age-related macular degeneration are most likely to develop exudation, research shows, according to a report in Medscape. The new technology can